We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens.
- Authors
Cotugno, Nicola; Franzese, Enrica; Angelino, Giulia; Amodio, Donato; Romeo, Erminia Francesca; Rea, Francesca; Faraci, Simona; Tambucci, Renato; Profeti, Elisa; Manno, Emma Concetta; Santilli, Veronica; Rotulo, Gioacchino Andrea; Pighi, Chiara; Medri, Chiara; Morrocchi, Elena; Colagrossi, Luna; Pascucci, Giuseppe Rubens; Valentini, Diletta; Villani, Alberto; Rossi, Paolo
- Abstract
Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 27 pIBD, as compared to 30 healthy controls (HC). Immunogenicity was measured by anti-SARS-CoV2 IgG (anti-S and anti-trim Ab) before vaccination, after 21 days (T21) and 7 days after the second dose (T28). The safety profile was investigated by close monitoring and self-reported adverse events. Vaccination was well tolerated, and short-term adverse events reported were only mild to moderate. Three out of twenty-seven patients showed IBD flare after vaccination, but no causal relationship could be established. Overall, pIBD showed a good humoral response upon vaccination compared to HC; however, pIBD on anti-TNFα treatment showed lower anti-S Ab titers compared to patients receiving other immune-suppressive regimens (p = 0.0413 at first dose and p = 0.0301 at second dose). These data show that pIBD present a good safety and immunogenicity profile following SARS-CoV-2 mRNA vaccination. Additional studies on the impact of specific immune-suppressive regimens, such as anti TNFα, on immunogenicity should be further investigated on larger cohorts.
- Subjects
CHILD patients; COVID-19 vaccines; INFLAMMATORY bowel diseases; IMMUNE response; HUMORAL immunity
- Publication
Vaccines, 2022, Vol 10, Issue 7, pN.PAG
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines10071109